[4] [5] Semaglutide works by mimicking the incretin hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways
To qualify for Wegovy, youll typically need one of the following: A BMI of 30 or higher (classified as obesity ), or A BMI of 27 or higher with at least one weight-related health condition Weight-related conditions may include: High blood pressure (hypertension) High cholesterol (dyslipidemia) Type 2 diabetes Heart disease Obstructive sleep apnea Polycystic ovary syndrome ( PCOS ) In addition, in March 2024 the FDA expanded Wegovys approval to include reducing the risk of major cardiovascular events like heart attac k, stroke, and cardiovascular death in adults with cardiovascular disease plus overweight or obesity
Tirzepatide products have their own refrigeration requirements that differ from semaglutide
"It's more cost effective, and I think that's been the major barrier to getting people these medications, is cost and coverage," Egan said
Tang, D., Chen, K., Huang, L
